Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating niemann-pick type C disease

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Tamura, Atsushi ^a   Yui, Nobuhiko ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; BIOLOGICAL MARKER; CHOLESTEROL; PLURONIC BLOCK COPOLYMER P123; POLOXAMER; ROTAXANE;

ANIMAL; ARTICLE; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECT; ERYTHROCYTE; FIBROBLAST; HUMAN; LYSOSOME; METABOLISM; NIEMANN PICK DISEASE; PATHOLOGY; POLYMERIZATION; PRIMARY CELL CULTURE; RAT; SYNTHESIS;

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL MARKERS; CHOLESTEROL; ERYTHROCYTES; FIBROBLASTS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LYSOSOMES; NIEMANN-PICK DISEASE, TYPE C; POLOXALENE; POLYMERIZATION; PRIMARY CELL CULTURE; RATS; ROTAXANES;

EID: 84896272633     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04356     Document Type: Article

References (50)

1. Futerman, A. H. & van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 554-565 (2004). (Pubitemid 38868584)
2. Chang, T.-Y. et al. Niemann-Pick type C disease and intracellular cholesterol trafficking. J. Biol. Chem. 280, 20917-20920 (2005). (Pubitemid 40805646)
3. Vanier, M. T. & Millat, G. Niemann-Pick disease type C. Clin. Genet. 64, 269-281 (2003). (Pubitemid 37236127)
4. Carstea, E. D. et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277, 228-231 (1997). (Pubitemid 27446076)
5. Griffin, L. D., Gong, W., Verot, L. & Mellon, S. H. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 10, 704-711 (2004). (Pubitemid 38937635)
6. Lloyd-Evans, E. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14, 1247-1255 (2008).
7. Xu, M. et al. d-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J. Biol. Chem. 287, 39349-39360 (2012).
8. Davis, M. E. & Brewster, M. E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3, 1023-1035 (2004). (Pubitemid 39642365)
9. Irie, T. & Uekama, K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36, 101-123 (1999). (Pubitemid 29074479)
10. Liu, B. Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease. Clin. Lipidol. 7, 289-301 (2012).
11. Rosenbaum, A. I., Zhang, G.,Warren, J. D. &;Maxfield, F. R. Endocytosis of betacyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc. Natl. Acad. Sci. USA 107, 5477-5482 (2010).
12. Peake, K. B. & Vance, J. E. Normalization of cholesterol homeostasis by 2-hydroxypropyl-b-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice. J. Biol. Chem. 287, 9290-9298 (2012).
13. Yancey, P. G. et al. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J. Biol. Chem. 27, 16026-16034 (1996). (Pubitemid 26236215)
14. Liu, B. et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc12/2 mouse. Proc. Natl. Acad. Sci. USA 106, 2377-2382 (2009).
15. Davidson, C. D. et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4, e6951 (2009).
16. Matsuo, M. et al. Effects of cyclodextrin in two patients with Niemann-Pick type C disease. Mol. Genet. Metab. 108, 76-81 (2013).
17. Frijlink, H. W. et al. The pharmacokinetics of b-cyclodextrin and hydroxypropylb-cyclodextrin in the rat. Pharm. Res. 7, 1248-1252 (1990).
18. Gould, S. & Scott, R. C. 2-Hydroxypropyl-b-cyclodextrin (HP-b-CD): a toxicology review. Food. Chem. Toxicol. 43, 1451-1459 (2005).
19. Onodera, R. et al. Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-b-cyclodextrin. Int. J. Pharm. 452, 116-123 (2013).
20. Kilsdonk, E. P. et al. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270, 17250-17256 (1995).
21. Irie, T. & Uekama, K. Pharmaceutical applications of cyclodextrins. III. toxicological issues and safety evaluation. J. Pharm. Sci. 86, 147-162 (1997). (Pubitemid 27078377)
22. Leroy-Lechat, F., Wouessidjewe, D., Andreux, J.-P., Puisieux, F. & Duchêne, D. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm. 101, 97-103 (1994).
23. Motoyama, K. et al. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-b-cyclodextrin, not 2,6-di-O-methyl-a-cyclodextrin, through cholesterol depletion from lipid rafts on plasmamembranes in cells. Eur. J. Pharm. Sci. 38, 249-261 (2009).
24. Onodera, R.,Motoyama, K., Okamatsu, A., Higashi, T. & Arima, H. Potential use of folate-appended methyl-b-cyclodextrin as an anticancer agent. Sci. Rep. 3, 1104; DOI:10.1038/srep01104 (2013).
25. Harada, A., Li, J. & Kamachi, M. The molecular necklace: a rotaxane containing many threaded a-cyclodextrins. Nature 356, 325-327 (1992).
26. Wenz, G., Han, B. H. & Müller, A. Cyclodextrin rotaxanes and polyrotaxanes. Chem. Rev. 106, 782-817 (2006).
27. Li, J. & Loh, X. J. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev. 60, 1000-1017 (2008).
28. Ooya, T. et al. Biocleavable polyrotaxane-plasmid DNA polyplex for enhanced gene delivery. J. Am. Chem. Soc. 128, 3852-3853 (2006).
29. Yamashita, A. et al. Synthesis of a biocleavable polyrotaxane-plasmid DNA (pDNA) polyplex and its use for the rapid nonviral delivery of pDNA to cell nuclei. Nat. Protoc. 1, 2861-2869 (2006).
30. Tamura, A. et al. Molecular logistics using cytocleavable polyrotaxanes for the reactivation of enzymes delivered in living cells. Sci. Rep. 3, 2252; DOI:10.1038/ srep02252 (2013).
31. Tamura, A. & Yui, N. Cellular internalization and gene silencing of siRNA polyplexes by cytocleavable cationic polyrotaxanes with tailored rigid backbones. Biomaterials 34, 2480-2491 (2013).
32. Meng, F., Hennink, W. E. & Zhong, Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 30, 2180-2198 (2009).
33. Collins, C. J. et al. Synthesis, characterization, and evaluation of pluronic-based bcyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick type C fibroblasts. Biochemistry 52, 3242-3253 (2013).
34. Mondjinou, Y. A. et al. Synthesis of 2-hydroxypropyl-b-cyclodextrin/ pluronicbased polyrotaxanes via heterogeneous reaction as potential Niemann-Pick type C therapeutics. Biomacromolecules 14, 4189-4197 (2013).
35. Fujita, H. Ooya, T. & Yui, N. Thermally induced localization of cyclodextrins in a polyrotaxane consisting of b-cyclodextrins and poly(ethylene glycol)-poly(propylene glycol) triblock copolymer. Macromolecules 32, 2534-2541 (1999). (Pubitemid 129587199)
36. Yui, N. et al. Inhibitory effect of supramolecular polyrotaxane-dipeptide conjugates on digested peptide uptake via intestinal human peptide transporter. Bioconjug. Chem. 13, 582-587 (2002). (Pubitemid 34527520)
37. Dan, K. & Ghosh, S. One-pot synthesis of an acid-labile amphiphilic triblock copolymer and its pH-responsive vesicular assembly. Angew. Chem. Int. Ed. 52, 7300-7305 (2013).
38. Tamura, A. & Yui, N. A supramolecular endosomal escape approach for enhancing gene silencing of siRNA using acid-degradable cationic polyrotaxanes. J. Mater. Chem. B 1, 3535-3544 (2013).
39. Liu, R. et al. pH-Responsive nanogated ensemble based on gold-capped mesoporous silica through an acid-labile acetal linker. J. Am. Chem. Soc. 132, 1500-1501 (2010).
40. Lange, Y., Ye, J., Rigney, M. & Steck, T. L. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J. Lipid Res. 40, 2264-2270 (1999). (Pubitemid 30017528)
41. Lange, Y., Ye, J., Rigney, M. & Steck, T. L. Dynamics of lysosomal cholesterol in Niemann-Pick type C and normal human fibroblasts. J. Lipid Res. 43, 198-204 (2002). (Pubitemid 34184006)
42. Lange, Y., Ye, J., Rigney, M.&Steck, T. L. Cholesterol movement inNiemann-Pick type C cells and in cells treated with amphiphiles. J. Biol. Chem. 275, 17468-17475 (2000). (Pubitemid 30430786)
43. Chang, T.-Y., Chang, C. C., Ohgami, N. & Yamauchi, Y. Cholesterol sensing, trafficking, and esterification. Annu. Rev. Cell. Dev. Biol. 22, 129-157 (2006).
44. Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340 (1997). (Pubitemid 27220877)
45. Mbua, N. E. et al. Abnormal accumulation and recycling of glycoproteins visualized in Niemann-Pick typeCcells using the chemical reporter strategy. Proc. Natl. Acad. Sci. USA 110, 10207-10212 (2013).
46. Yokoyama, N., Seo, J.-H., Tamura, A., Sasaki, Y. & Yui, N. Tailoring the supramolecular structure of aminated polyrotaxanes toward enhanced cellular internalization. Macromol. Biosci. in press; DOI:10.1002/mabi.201300198.
47. Mellman, I., Fuchs, R. & Helenius, A. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 55, 663-700 (1986). (Pubitemid 16070784)
48. Arunachalam, B., Phan, U. T., Geuze, H. J. & Cresswell, P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. USA 97, 745-750 (2000). (Pubitemid 30070380)
49. Abi-Mosleh, L., Infante, R. E., Radhakrishnan, A., Goldstein, J. L. & Brown, M. S. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells. Proc. Natl. Acad. Sci. USA 106, 19316-19321 (2009).
50. Nakamuta, M. et al. Impact of cholesterol metabolism and the LXRa-SREBP-1c pathway on nonalcoholic fatty liver disease. Int. J. Mol. Med. 23, 603-608 (2009).